BRVO - BRANCH RETINAL VEIN OCCLUSION
Clinical trials for BRVO - BRANCH RETINAL VEIN OCCLUSION explained in plain language.
Never miss a new study
Get alerted when new BRVO - BRANCH RETINAL VEIN OCCLUSION trials appear
Sign up with your email to follow new studies for BRVO - BRANCH RETINAL VEIN OCCLUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug EYE201 aims to tackle blinding swelling
Disease control OngoingThis early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, for people with vision loss due to swelling in the back of the eye. The study includes patients with three different eye conditions: branch retinal vein occlusion, diabetic macular…
Matched conditions: BRVO - BRANCH RETINAL VEIN OCCLUSION
Phase: PHASE1, PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New syringe design tested for common eye disease treatment
Disease control OngoingThis study tests whether a pre-filled syringe is as safe as the standard vial when giving an eye injection for wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. About 120 people will receive the drug ONS-5010 (bevacizumab) either from…
Matched conditions: BRVO - BRANCH RETINAL VEIN OCCLUSION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC